essions are intended to identify forward-looking statements, although
not all forward-looking statements contain these identifying words. The
Company's forward-looking statements are subject to a number of known and
unknown risks and uncertainties that could cause actual results,
performance or achievements to differ materially from those described or
implied in the forward-looking statements, including, but not limited to,
our ability to secure FDA approval for our product candidates under Section
505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to
market, commercialize and achieve market acceptance for product candidates
developed using our VIAdel(TM) technology; the progress or success of our
research, development and clinical programs, the initiation and completion
of our clinical trials, the timing of the interim analyses and the timing
or success of our product candidates, particularly VIAject(TM) and
VIAtab(TM); our ability to secure patents for VIAject(TM) and our other
product candidates; our ability to protect our intellectual property and
operate our business without infringing upon the intellectual property
rights of others; our estimates of future performance; our ability to enter
into collaboration arrangements for the commercialization of our product
candidates and the success or failure of those collaborations after
consummation, if consummated; the rate and degree of market acceptance and
clinical utility of our products; our commercialization, marketing and
manufacturing capabilities and strategy; our estimates regarding
anticipated operating losses, future revenues, capital requirements and our
needs for additional financing; and other factors identified in our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. The
Company disclaims any obligation to update any forward-looking statements
as a result of events occurring after the date of this press release.
'/>"/>SOURCE Biodel Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies2.
Wisconsin firms to present at Cleantech venture capital event3.
New Sonic Foundry search engine finds words, phrases in video presentations4.
Lone Wisconsin firm to present at InvestMidwest5.
Sonic Foundry creates search engine for 7,000 expert video presentations6.
InvestMidWest calls for business presentations7.
Wicab to present BrainPort at Boston conference8.
Three more Wisconsin firms to present at venture forum9.
Six Wisconsin firms to present at BIO Mid-America VentureForum10.
New Health and Human Services representative for Midwest11.
Top 20 big pharmas represent majority of world pharma market